Lixte Biotechnology Holdings, INC 8-K filings

LIXTE Biotechnology reveals new pre-clinical data demonstrating how its lead compound, LB-100, is metabolized into its active form, potentially leading to a biomarker strategy for patient selection.

LIXTE Biotechnology Holdings, Inc. announces the addition of Northwestern University's Lurie Cancer Center as a second site for its clinical trial combining LB-100 with GSK's Dostarlimab to treat ovarian clear cell cancer, with patient recruitment underway and the first patient dosed.

Lixte Biotechnology Holdings, Inc. received a delisting notification from Nasdaq after failing to meet the minimum stockholders' equity requirement, and intends to appeal the decision.

Lixte Biotechnology Holdings, Inc. closed a registered direct offering, raising $1.05 million through the sale of common stock and warrants.

Lixte Biotechnology Holdings, Inc. has entered into an agreement to sell up to $1.7 million of its common stock through an at-the-market offering.

Lixte Biotechnology Holdings, Inc. reports the resignation of its Vice President and Chief Operating Officer, Eric Forman, effective December 31, 2024.

Lixte Biotechnology Holdings held its annual meeting on December 19, 2024, where shareholders elected directors, ratified the accounting firm, and approved executive compensation on an advisory basis.

Lixte Biotechnology has amended its collaboration agreement with the Netherlands Cancer Institute and Oncode Institute, pausing study activities until a Phase 1b clinical trial for LB-100 in colorectal cancer begins.

Lixte Biotechnology has received an extension until February 18, 2025, from Nasdaq to meet the minimum stockholders' equity requirement, following a previous non-compliance notice.

Lixte Biotechnology has received a Notice of Allowance from the USPTO for a patent covering the combination of its LB-100 compound with various cancer immunotherapies.

Lixte Biotechnology has dosed the first patient in a new clinical trial for unresponsive metastatic colorectal cancer, collaborating with the Netherlands Cancer Institute and supported by Roche.

Lixte Biotechnology Holdings, Inc. received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

Lixte Biotechnology is set to present at two investor conferences and has provided updates on its clinical trial activities, including new collaborations and a key appointment.

Lixte Biotechnology Holdings, Inc. has terminated its clinical research support agreement with City of Hope for a Phase 1b trial of LB-100 in combination therapy for small cell lung cancer.

Lixte Biotechnology Holdings, Inc. has amended its board compensation plan to issue stock options instead of cash to non-officer directors, including Dr. Rene Bernards, to preserve cash.

LIXTE Biotechnology is collaborating with Roche and the Netherlands Cancer Institute to conduct a clinical trial for immune therapy unresponsive metastatic colon cancer using LIXTE's lead compound, LB-100, and Roche's atezolizumab.

Lixte Biotechnology has partnered with the Netherlands Cancer Institute to initiate a Phase 1b/2 clinical trial combining its drug LB-100 with Roche's atezolizumab for metastatic colon cancer.

Lixte Biotechnology Holdings has appointed Dr. Jan Schellens as its new Chief Medical Officer, effective August 1, 2024, succeeding Dr. James Miser.

Lixte Biotechnology Holdings has announced that the employment agreement with its Chief Medical Officer, Dr. James Miser, will not be renewed and will expire on July 31, 2024.

Lixte Biotechnology announced progress in pre-clinical studies of its compound LB-100, showing potential in a new area of cancer biology called activation lethality, alongside updates on ongoing clinical trials.

Lixte Biotechnology is co-sponsoring a scientific conference at Harvard's Dana Farber Cancer Institute, focusing on a unique cancer therapy approach involving the over-activation of oncogenic signaling.

Lixte Biotechnology announced the publication of pre-clinical data showing its lead compound, LB-100, can force cancer cells to lose their cancer-causing properties.

Lixte Biotechnology announced progress in clinical trials for its cancer therapy, LB-100, including a new patent license and positive pre-clinical data.

Lixte Biotechnology announced that Dr. Ren Bernards will present new pre-clinical data on their lead compound, LB-100, at a major cancer research conference in Dublin.

Lixte Biotechnology has entered into an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and the National Cancer Institute to develop cancer therapies.

Lixte Biotechnology has dosed the first patient in a Phase 1b/2 clinical trial evaluating the combination of its drug LB-100 with GSK's immunotherapy dostarlimab-gxly for ovarian clear cell carcinoma.